Table 4.
Comparison between COVID-19 patients who survived vs. those who died
| Variable | COVID-19, died N = 24a | COVID-19, survived N = 76a | p-valub |
|---|---|---|---|
| Age | 58 (52, 63) | 47 (41, 56) | < 0.001 |
| Gender (male) | 24 (100%) | 70 (92%) | 0.023 |
| BMI (kg/m2) | 25.7 (24.5, 29.7) | 27.5 (25.4, 32.1) | 0.072 |
| Ethnicity | |||
| Middle East | 1 (4.1%) | 2 (2.6%) | 0.14 |
| North Africa | 0 (0%) | 1 (1.3%) | |
| Northeast Africa | 2 (8.2%) | 4 (5.2%) | |
| South Asia | 18 (75%) | 63 (82.8%) | |
| Southeast Asia | 2 (8.2%) | 5 (6.5%) | |
| Western Asia | 1 (4.1%) | 1 (1.3%) | |
| Duration of MV (days) | 25 (19, 41) | 8 (5, 18) | < 0.001 |
| ICU LoS (days) | 26 (20, 48) | 15 (11, 29) | < 0.001 |
| ECMO | 7 (29%) | 10 (13%) | 0.001 |
| Nosocomial infections | 22 (92%) | 42 (55.2%) | < 0.001 |
| Convalescent plasma therapy | 9 (37.5%) | 25 (32.8%) | 0.4 |
| Diabetes status | |||
| No diabetes | 15 (62.5%) | 41 (53.9%) | 0.14 |
| Pre-diabetes | 1 (4.1%) | 4 (5.2%) | |
| Diabetes | 8 (33.4%) | 31 (40.7%) | |
| Hypertension | 11 (46%) | 31 (40.7%) | 0.5 |
| Coronary artery disease | 1 (4.1%) | 4 (6.2%) | 0.8 |
| Chronic kidney failure | 3 (12.5%) | 8 (10.5%) | 0.3 |
| Chronic heart failure | 1 (4.1%) | 3 (3.9%) | 0.9 |
Data are represented as numbers (%) per each category for categorical variables and as median (Interquartile range, IQR) for continuous variables
ECMO extracorporeal membrane oxygenation, LoS length of stay, MV mechanical ventilation
aMedian (IQR); n (%)
bWilcoxon rank-sum test; Fisher's exact test; Pearson's Chi-squared test
P-values were calculated with Fisher exact test or Wilcoxon rank-sum test